HDAC Inhibition Induces Patient-Specific Phenotypic Remodeling in Glioblastoma Organoids

Technical Summary: HDAC Inhibition Induces Patient-Specific Phenotypic Remodeling in Glioblastoma Organoids

Problem Statement
Glioblastoma (GBM) remains the most aggressive primary brain tumor in adults, characterized by rapid progression, therapeutic resistance, and poor prognosis. A defining feature of GBM is its profound intra- and intertumoral heterogeneity, driven by genetic and epigenetic alterations that regulate tumor cell identity and plasticity. While histone deacetylase (HDAC) inhibitors (HDACi) have shown antitumor activity in conventional cell lines, their biological effects are highly context-dependent. A critical gap exists in understanding how HDAC inhibition functions in models that faithfully preserve the spatial organization, cellular diversity, and patient-specific heterogeneity of human glioblastomas. Conventional two-dimensional (2D) cultures and immortalized cell lines often fail to recapitulate these complex features, limiting the translational relevance of preclinical findings.

Methodology
The study employed patient-derived glioblastoma organoids (gPDOs) as a translational platform to investigate the effects of pharmacological HDAC inhibition.

• Model Generation: Two independent gPDO models (gPDO #983002 and gPDO #982147) were established from fresh surgical resections of patients with distinct clinical characteristics. These models were maintained in 3D culture under orbital agitation to support self-organization into spheroidal structures.
• Characterization: Organoids were validated via histological staining (H&E) and immunofluorescence for lineage-associated markers (GFAP, Nestin, βIII-tubulin, SOX2, S100β) and histone H4 acetylation (H4ac).
• Intervention: Organoids were treated with two broad-spectrum HDAC inhibitors: Trichostatin A (TSA, 200 nM) and Vorinostat/SAHA (500 nM), compared against a DMSO vehicle control.
• Assays:
  • Growth Analysis: Organoid expansion was quantified via bright-field imaging and area measurement over 48 hours.
  • Molecular Profiling: RT-qPCR was performed on matched patient-derived cell lines to assess basal expression of HDAC1–HDAC8. Immunofluorescence was used to quantify changes in H4ac and lineage markers after 72 hours of treatment.
  • Bioinformatics: Publicly available datasets (TCGA via cBioPortal and GEPIA3) were analyzed to correlate HDAC expression with GBM markers and patient survival. Protein-protein interaction networks were generated using the STRING database.

Key Results

1. Validation of gPDO Models: Both gPDO models successfully recapitulated the histopathological features of high-grade glioma, including high cellularity, pleomorphism, and the presence of stem-like (Nestin, SOX2) and glial-lineage (GFAP, S100β) populations. The models retained patient-specific features, as evidenced by subtle morphological differences and differential sensitivity to temozolomide in matched cell cultures.
2. Basal HDAC Heterogeneity: RT-qPCR revealed significant inter-patient heterogeneity in basal HDAC expression. GB983002 predominantly expressed HDAC2, while GB982147 showed elevated HDAC2 alongside increased levels of HDAC5, HDAC7, and HDAC8.
3. Differential Epigenetic Response: Both TSA and SAHA effectively increased histone H4 acetylation (H4ac) in both models, confirming target engagement. However, the magnitude and pattern of acetylation varied; notably, SAHA induced higher H4ac levels than TSA in gPDO #983002, whereas SAHA resulted in reduced H4ac staining compared to TSA in gPDO #982147.
4. Patient-Specific Phenotypic Remodeling: HDAC inhibition elicited distinct, patient-specific phenotypic responses:
   • gPDO #983002: Treatment with both TSA and SAHA resulted in a generalized suppression of lineage markers, significantly reducing GFAP, Nestin, and βIII-tubulin expression.
   • gPDO #982147: The response was divergent and marker-specific. GFAP decreased only with SAHA; Nestin increased with TSA but decreased with SAHA; and βIII-tubulin was reduced by both inhibitors.
5. Growth Inhibition: Both inhibitors attenuated organoid growth compared to controls, though the magnitude of suppression varied between the two models and over time.
6. Bioinformatic Correlations: Analysis of TCGA data showed positive correlations between HDAC1/HDAC2 expression and GBM-associated markers (SOX2, NES, GFAP). High HDAC2 expression was associated with the shortest median overall survival (8.8 months) in the analyzed cohort. Network analysis linked HDACs to stemness and lineage specification pathways, including Notch–HLH and ERBB4 signaling.

Significance and Claims
The authors claim that their findings establish patient-derived gPDOs as valuable translational platforms for evaluating individualized responses to epigenetic therapies. The study demonstrates that:

• Biological Heterogeneity: GBM exhibits substantial heterogeneity not only in basal HDAC expression but also in epigenetic responses to HDAC inhibition.
• Non-Uniformity of Therapy: Epigenetic modulation does not elicit a uniform biological response across glioblastoma specimens; identical pharmacological interventions can generate opposing phenotypic outcomes depending on the intrinsic molecular background of the tumor.
• Clinical Relevance: The preservation of patient-specific characteristics in gPDOs allows for the investigation of therapeutic heterogeneity that is often lost in conventional models.
• Therapeutic Rationale: The association between HDAC2 expression, aggressive molecular signatures, and poor survival supports the rationale for targeting HDAC-mediated epigenetic mechanisms in glioblastoma, particularly within patient-specific contexts.

The paper concludes that while HDAC inhibition remodels key biological features such as histone acetylation, growth dynamics, and lineage-associated programs, these effects are strictly patient-dependent. The authors acknowledge limitations regarding the small sample size (two patients) and the lack of comprehensive transcriptomic or proteomic follow-up, suggesting that future studies with larger cohorts are necessary to validate these findings and identify predictive biomarkers.